78 related articles for article (PubMed ID: 21709420)
1. Intravenous recombinant tissue plasminogen activator therapy for stroke patients receiving maintenance hemodialysis: the Stroke Acute Management with Urgent Risk-Factor Assessment and Improvement (SAMURAI) rt-PA registry.
Naganuma M; Mori M; Nezu T; Makihara N; Koga M; Okada Y; Minematsu K; Toyoda K;
Eur Neurol; 2011; 66(1):37-41. PubMed ID: 21709420
[TBL] [Abstract][Full Text] [Related]
2. Early neurological deterioration within 24 hours after intravenous rt-PA therapy for stroke patients: the Stroke Acute Management with Urgent Risk Factor Assessment and Improvement rt-PA Registry.
Mori M; Naganuma M; Okada Y; Hasegawa Y; Shiokawa Y; Nakagawara J; Furui E; Kimura K; Yamagami H; Kario K; Okuda S; Koga M; Minematsu K; Toyoda K
Cerebrovasc Dis; 2012; 34(2):140-6. PubMed ID: 22854333
[TBL] [Abstract][Full Text] [Related]
3. Pretreatment ASPECTS on DWI predicts 3-month outcome following rt-PA: SAMURAI rt-PA Registry.
Nezu T; Koga M; Kimura K; Shiokawa Y; Nakagawara J; Furui E; Yamagami H; Okada Y; Hasegawa Y; Kario K; Okuda S; Nishiyama K; Naganuma M; Minematsu K; Toyoda K
Neurology; 2010 Aug; 75(6):555-61. PubMed ID: 20697108
[TBL] [Abstract][Full Text] [Related]
4. Reduced estimated glomerular filtration rate is associated with stroke outcome after intravenous rt-PA: the Stroke Acute Management with Urgent Risk-Factor Assessment and Improvement (SAMURAI) rt-PA registry.
Naganuma M; Koga M; Shiokawa Y; Nakagawara J; Furui E; Kimura K; Yamagami H; Okada Y; Hasegawa Y; Kario K; Okuda S; Nishiyama K; Minematsu K; Toyoda K
Cerebrovasc Dis; 2011; 31(2):123-9. PubMed ID: 21088392
[TBL] [Abstract][Full Text] [Related]
5. Arterial occlusion sites on magnetic resonance angiography influence the efficacy of intravenous low-dose (0.6 mg/kg) alteplase therapy for ischaemic stroke.
Nakashima T; Toyoda K; Koga M; Matsuoka H; Nagatsuka K; Takada T; Naritomi H; Minematsu K
Int J Stroke; 2009 Dec; 4(6):425-31. PubMed ID: 19930051
[TBL] [Abstract][Full Text] [Related]
6. Effect of serum lipid levels on stroke outcome after rt-PA therapy: SAMURAI rt-PA registry.
Makihara N; Okada Y; Koga M; Shiokawa Y; Nakagawara J; Furui E; Kimura K; Yamagami H; Hasegawa Y; Kario K; Okuda S; Naganuma M; Toyoda K
Cerebrovasc Dis; 2012; 33(3):240-7. PubMed ID: 22261711
[TBL] [Abstract][Full Text] [Related]
7. Early ischemic change on CT versus diffusion-weighted imaging for patients with stroke receiving intravenous recombinant tissue-type plasminogen activator therapy: stroke acute management with urgent risk-factor assessment and improvement (SAMURAI) rt-PA registry.
Nezu T; Koga M; Nakagawara J; Shiokawa Y; Yamagami H; Furui E; Kimura K; Hasegawa Y; Okada Y; Okuda S; Kario K; Naganuma M; Maeda K; Minematsu K; Toyoda K
Stroke; 2011 Aug; 42(8):2196-200. PubMed ID: 21719764
[TBL] [Abstract][Full Text] [Related]
8. CHADS2 score is associated with 3-month clinical outcomes after intravenous rt-PA therapy in stroke patients with atrial fibrillation: SAMURAI rt-PA Registry.
Koga M; Kimura K; Shibazaki K; Shiokawa Y; Nakagawara J; Furui E; Yamagami H; Okada Y; Hasegawa Y; Kario K; Okuda S; Naganuma M; Nezu T; Maeda K; Minematsu K; Toyoda K
J Neurol Sci; 2011 Jul; 306(1-2):49-53. PubMed ID: 21492878
[TBL] [Abstract][Full Text] [Related]
9. [Prospects of thrombolytic therapy for acute ischemic stroke].
Nakashima T; Minematsu K
Brain Nerve; 2009 Sep; 61(9):1003-12. PubMed ID: 19803399
[TBL] [Abstract][Full Text] [Related]
10. Intravenous recombinant tissue plasminogen activator therapy for acute ischemic stroke: initial Israeli experience.
Schwammenthal Y; Drescher MJ; Merzeliak O; Tsabari R; Bruk B; Feibel M; Hoffman C; Bakon M; Rotstein Z; Chapman J; Tanne D
Isr Med Assoc J; 2004 Feb; 6(2):70-4. PubMed ID: 14986460
[TBL] [Abstract][Full Text] [Related]
11. Recanalization of middle cerebral artery and intracranial aneurysm in the same ischemic territory with intravenous administration of recombinant tissue plasminogen activator: case report.
Matsuzaki T; Yoshino A; Sakatani K; Katayama Y
J Stroke Cerebrovasc Dis; 2011; 20(3):269-72. PubMed ID: 20630773
[TBL] [Abstract][Full Text] [Related]
12. [Intravenous tissue plasminogen activator (t-PA) for acute ischemic stroke in a local university hospital].
Takahashi K; Iijima K; Oguro H; Bokura H; Nagai A; Yamaguchi S; Kobayashi S
No To Shinkei; 2005 Aug; 57(8):683-8. PubMed ID: 16146212
[TBL] [Abstract][Full Text] [Related]
13. Predictors of major neurological improvement after intravenous thrombolysis in acute ischemic stroke: a hospital-based study from south India.
Boddu DB; Srinivasarao Bandaru VC; Reddy PG; Madhusudan M; Rukmini MK; Suryaprabha T; Jabeen SA; Suvarna A; Jayalakshmi SS; Meena AK; Borgohain R; Kaul S
Neurol India; 2010; 58(3):403-6. PubMed ID: 20644268
[TBL] [Abstract][Full Text] [Related]
14. Recanalization between 1 and 24 hours after t-PA therapy is a strong predictor of cerebral hemorrhage in acute ischemic stroke patients.
Kimura K; Iguchi Y; Shibazaki K; Kobayashi K; Uemura J; Aoki J; Yamashita S; Terasawa Y; Matsumoto N
J Neurol Sci; 2008 Jul; 270(1-2):48-52. PubMed ID: 18304581
[TBL] [Abstract][Full Text] [Related]
15. Endogenous activated protein C predicts hemorrhagic transformation and mortality after tissue plasminogen activator treatment in stroke patients.
Mendioroz M; Fernández-Cadenas I; Alvarez-Sabín J; Rosell A; Quiroga D; Cuadrado E; Delgado P; Rubiera M; Ribó M; Molina C; Montaner J
Cerebrovasc Dis; 2009; 28(2):143-50. PubMed ID: 19546541
[TBL] [Abstract][Full Text] [Related]
16. Comparison of combined venous and arterial thrombolysis with primary arterial therapy using recombinant tissue plasminogen activator in acute ischemic stroke.
Wolfe T; Suarez JI; Tarr RW; Welter E; Landis D; Sunshine JL; Zaidat OO
J Stroke Cerebrovasc Dis; 2008; 17(3):121-8. PubMed ID: 18436152
[TBL] [Abstract][Full Text] [Related]
17. Intravenous thrombolysis with rt-PA in acute ischemic stroke patients aged older than 80 years in Italy.
Toni D; Lorenzano S; Agnelli G; Guidetti D; Orlandi G; Semplicini A; Toso V; Caso V; Malferrari G; Fanucchi S; Bartolomei L; Prencipe M
Cerebrovasc Dis; 2008; 25(1-2):129-35. PubMed ID: 18073466
[TBL] [Abstract][Full Text] [Related]
18. Does mild deficit for patients with stroke justify the use of intravenous tissue plasminogen activator?
Hassan AE; Zacharatos H; Hassanzadeh B; El-Gengaihy A; AlKawi A; Shhadeh A; Kirmani JF
J Stroke Cerebrovasc Dis; 2010 Mar; 19(2):116-20. PubMed ID: 20189087
[TBL] [Abstract][Full Text] [Related]
19. Impact of the approval of intravenous recombinant tissue plasminogen activator therapy on the processes of acute stroke management in Japan: the Stroke Unit Multicenter Observational (SUMO) Study.
Sato S; Uehara T; Toyoda K; Yasui N; Hata T; Ueda T; Okada Y; Toyota A; Hasegawa Y; Naritomi H; Minematsu K;
Stroke; 2009 Jan; 40(1):30-4. PubMed ID: 18948604
[TBL] [Abstract][Full Text] [Related]
20. Influence of pretreatment MRI parameters on clinical outcome, recanalization and infarct size in 49 stroke patients treated by intravenous tissue plasminogen activator.
Derex L; Nighoghossian N; Hermier M; Adeleine P; Berthezène Y; Philippeau F; Honnorat J; Froment JC; Trouillas P
J Neurol Sci; 2004 Oct; 225(1-2):3-9. PubMed ID: 15465079
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
